Plasma Proteins Associated With the Immune Response to Anthracycline Cardiotoxicity in Patients With Hematologic Malignancies
- 27 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
Abstract
BACKGROUND: Anthracyclines such as doxorubicin are well recognized to induce dose-dependent cardiotoxicity. However, traditional imaging and blood biomarkers of myocardial injury are inadequate for early risk stratification. We aimed to discover plasma proteins that correlate with the subsequent development of anthracycline-induced systolic dysfunction in patients, with validation studies in preclinical models. METHODS: We used an aptamer-based proteomics platform to measure over 7000 proteins in the plasma obtained at baseline (before anthracycline chemotherapy) in a prospectively enrolled cohort of patients with hematologic malignancies (n=34). The correlation between protein levels and change in left ventricular ejection fraction was assessed. Candidate biomarkers were validated in a second patient cohort treated with anthracyclines for hematologic malignancies (n=32), as well as in a mouse model of delayed doxorubicin cardiotoxicity. RESULTS: In both discovery and validation cohorts, baseline levels of CPVL (carboxypeptidase vitellogenic-like protein) and PIGR (poly immunoglobulin receptor) measured in the plasma before anthracycline treatment correlated with a subsequent decline in left ventricular ejection fraction (PIGR: R =−0.74; P =0.0022; CPVL: R =−0.74; P =0.0022). Findings were confirmed in human plasma samples using ELISA or Western blot, and similar changes in proteins were observed in mice treated with doxorubicin. In further support of PIGR as a biomarker representing the systemic adaptive immune response, doxorubicin treatment was associated with increased circulating levels of IgA + (immunoglobulin A) B cells in mice, which similarly correlated with the decline in left ventricular ejection fraction. The highest quartile of PIGR and CPVL levels was associated with decreased overall survival but not progression-free survival. CONCLUSIONS: Preanthracycline levels of the plasma immunologic proteins CPVL and PIGR were associated with a subsequent decline in cardiac function, representing potentially new inflammatory biomarkers of anthracycline cardiotoxicity.Keywords
This publication has 42 references indexed in Scilit:
- Sex Differences in the Development of Anthracycline-Associated Heart FailureJournal of Cardiac Failure, 2023
- Infiltrating macrophages amplify doxorubicin-induced cardiac damage: role of catecholaminesCellular and Molecular Life Sciences, 2023
- CPVL suppresses metastasis of nasopharyngeal carcinoma through inhibiting epithelial–mesenchymal transitionJournal of Cancer Research and Clinical Oncology, 2023
- Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010JAMA Network Open, 2023
- Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal InjuryJACC: Basic To Translational Science, 2023
- Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinomaHepatology, 2017
- CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)International Journal of Cancer, 2015
- Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathyBasic Research in Cardiology, 2010
- Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathyEuropean Heart Journal, 2004
- Cloning and Characterization of CPVL, a Novel Serine Carboxypeptidase, from Human MacrophagesGenomics, 2001